I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced that it has entered into a strategic collaboration agreement with Jumpcan Pharmaceutical Group (Jumpcan), a leading China pharmaceutical company specialized in and committed to pediatric medicines, for the development, manufacturing and commercialization of I-Mab
